logo
logo

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate From Sintetica

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate From Sintetica

07/27/21, 11:01 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgnashville
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‐focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions, to acquire the marketing and supply rights in the U.S. and Canada for AMP-100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections, which are estimated to total over 10 million procedures annually in the U.S.(1)

Company Info

Company
HARROW HEALTH, INC.
Location
102 woodmont blvd.
Nashville, Arkansas, United States
Company info
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Related People